William Polvino
Director/Board Member chez SAB BIOTHERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
William J.
Polvino currently works at Bridge Medicines LLC, as Chief Executive Officer & Director from 2017, SAB Sciences, Inc., as Director from 2019, and SAB Biotherapeutics, Inc., as Independent Director from 2021.
Dr. Polvino also formerly worked at Sapphire Therapeutics, Inc., as President & Chief Executive Officer from 2002 to 2009, Veloxis Pharmaceuticals A, as President & Chief Executive Officer from 2011 to 2015, Helsinn Therapeutics (U.S.), Inc., as President & Chief Executive Officer, Big Cypress Acquisition Corp., as Independent Director, Merck & Co., Inc., as Principal, and Innoviva, Inc., as Vice President-Clinical Affairs.
Dr. Polvino received his doctorate degree from the University of Medicine & Dentistry of New Jersey and undergraduate degree from Boston College.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
18/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de William Polvino
Sociétés | Poste | Début |
---|---|---|
SAB BIOTHERAPEUTICS, INC. | Director/Board Member | 22/10/2021 |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Chief Executive Officer | 27/03/2017 |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The private company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Director/Board Member | 01/01/2019 |
Anciens postes connus de William Polvino
Sociétés | Poste | Fin |
---|---|---|
VELOXIS PHARMACEUTICALS A/S | Chief Executive Officer | 10/12/2015 |
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | President | 01/01/2009 |
BIG CYPR | Director/Board Member | - |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Chief Executive Officer | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Formation de William Polvino
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Boston College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
INNOVIVA, INC. | Health Technology |
SAB BIOTHERAPEUTICS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Sapphire Therapeutics, Inc.
Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Health Technology |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The private company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Health Technology |
Big Cypress Acquisition Corp.
Big Cypress Acquisition Corp. Financial ConglomeratesFinance Big Cypress Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on November 12, 2020 and is headquartered in Miami Beach, FL. | Finance |